Essential Updates in the Surgical Management of Inflammatory Bowel Disease: Current Topics From 2024 to Mid‐2026 Authors: Yoshiki Okita, Tadanobu Shimura, Mikio Kawamura, Yuhki Koike, Yuji Toiyama Published: 2026 ABSTRACT ABSTRACTInflammatory bowel disease management has undergone a major transformation with the introduction of treat‐to‐target strategies and highly effective biologic and small‐molecule therapies. Although these advances have reduced the overall requirement for surgery, operative intervention remains essential for selected patients with ulcerative colitis (UC) and Crohn's disease (CD). Additionally, the role of surgery has evolved considerably, driven by changes in the disease phenotype, advances in minimally invasive techniques, and growing interest in disease‐modifying surgical strategies. In UC, colectomy rates have declined, while surgical indications have increasingly shifted toward acute severe colitis, dysplasia, and colorectal cancer. Minimally invasive approaches, including robotic‐assisted and transanal techniques, have expanded rapidly and are associated with improved perioperative and functional outcomes. In CD, overall surgical rates have decreased; however, surgery remains indispensable for fibrostenotic, penetrating, and perianal disease. Recent developments include increasing evidence supporting Kono‐S anastomosis for reducing postoperative recurrence and ongoing investigation of mesentery‐based surgical strategies. Robotic‐assisted ileocolic resection has emerged as a safe and feasible minimally invasive option in selected patients. The prevention of postoperative recurrence has evolved toward risk‐stratified prophylaxis, early biologic therapy, and treat‐to‐target monitoring. In perianal CD, multidisciplinary management combining medical and surgical treatment remains the cornerstone of care, while newer biologics and small‐molecule therapies continue to expand therapeutic options. This review summarizes the major advances in the surgical management of UC and CD reported between January 2024 and June 2026 and highlights the evolving role of surgery in contemporary multidisciplinary care of inflammatory bowel disease.Keywords: Crohn's disease, extended mesenteric resection, perianal Crohn's disease, robotic surgery, ulcerative colitis Introduction Inflammatory bowel disease (IBD) management has entered an era of disease modification. Over the past decade, advances in therapeutic strategies and the rapid expansion of treatment options have fundamentally changed the natural history of ulcerative colitis (UC) and Crohn's disease (CD). The introduction of treat‐to‐target principles, together with the availability of highly effective biologic and small‐molecule therapies, including selective interleukin‐23 inhibitors, Janus kinase inhibitors, and sphingosine‐1‐phosphate receptor modulators, has enabled more precise and proactive disease control than before this introduction [1, 2, 3]. These advances have shifted treatment goals beyond symptom control toward objective measures of disease modification, including endoscopic healing, normalization of inflammatory biomarkers, steroid‐free remission, and prevention of cumulative bowel damage [1, 4]. Consequently, tight disease monitoring, therapeutic drug optimization, and multidisciplinary care have become integral components of modern IBD management, reflecting a growing emphasis on long‐term disease modification rather than short‐term symptom relief [4]. Despite these remarkable advances, surgery remains an indispensable component of IBD care. Although the overall requirement for surgery has declined, the characteristics of patients requiring surgical intervention have changed substantially. Based on these rapid developments, surgeons must not only understand contemporary operative techniques but also appreciate the evolving role of surgery within the broader therapeutic landscape of IBD [5, 6]. This review summarizes the major advances in the surgical management of UC and CD reported between January 2024 and June 2026, focusing on evolving surgical indications, minimally invasive surgery, prevention of postoperative recurrence, and multidisciplinary treatment strategies. Literature Search A literature search was conducted using PubMed to identify relevant studies published from January 2024 to June 2026. Search terms included “ulcerative colitis,” “Crohn's disease,” “surgery,” “robotic surgery,” “transanal surgery,” “ileal pouch–anal anastomosis,” “pouchitis,” “Kono‐S,” “mesenteric resection,” “postoperative recurrence,” and “perianal Crohn's disease.” Original studies, systematic reviews, meta‐analyses, and relevant guidelines addressing recent advances in the surgical management of IBD were included. Additional relevant studies were identified from the reference lists of selected articles. Given the narrative nature of this review, studies were selected based on their clinical relevance and contribution to recent developments in IBD surgery. UC Changing Surgical Trends in UC The surgical landscape of UC has changed substantially over the past two decades. Although colectomy remains a definitive treatment for medically refractory disease and disease‐related complications, the widespread adoption of biologics and small‐molecule therapies has considerably reduced the requirement for surgery in many patients [7]. A recent systematic review and meta‐analysis involving 294 359 patients showed that the cumulative risk of colectomy increases with the disease duration, but overall colectomy rates have steadily declined over the last three decades [7]. Recent population‐based studies further support this trend. In England, the 5‐year cumulative incidence of elective colectomy decreased from 2.97% to 1.59% between 2003 and 2020, coinciding with a marked increase in the use of advanced therapies [8]. Similar findings have been reported in Japan, where the introduction of antitumor necrosis factor (TNF) agents and calcineurin inhibitors was associated with a reduction in surgical rates [9]. Importantly, contemporary changes in UC surgery extend beyond a simple decline in colectomy rates [8]. The indications for surgery have evolved, with a decreasing proportion of operations performed for medically refractory disease and an increasing proportion performed for acute severe UC, colorectal neoplasia, and UC‐associated cancer. As medical therapies become more effective at controlling inflammatory activity, surgery is increasingly reserved for patients with irreversible disease‐related complications or malignancy. In parallel, surgical practice has shifted toward minimally invasive approaches and staged procedures. National data from Germany showed stable proctocolectomy rates despite increasing disease prevalence, whereas colectomy performed as the initial stage of a multistage restorative strategy became more common [10]. These findings likely reflect greater use of staged surgery in high‐risk patients and increasing emphasis on perioperative optimization. Taken together, these findings suggest that modern UC surgery is characterized not only by declining colectomy rates but also by evolving surgical indications, greater procedural complexity, and increasing integration with advanced medical therapy. Understanding these changing trends is essential for optimizing multidisciplinary management in the biologic era. Minimally Invasive Surgery in UC Minimally invasive surgery has become the standard surgical approach for UC, offering a faster recovery and shorter hospital stay while maintaining comparable safety and functional outcomes to open surgery. Recent advances in minimally invasive surgery have focused on robotic‐assisted and transanal techniques, which aim to overcome the technical challenges of pelvic dissection and pouch construction [11]. Studies published in 2024 and June 2026 highlight the expanding role of these approaches in improving perioperative and functional outcomes following restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA) (Tables 1, and 2) [12, 13, 14, 15, 16, 17, 18, 19, 20]. TABLE 1Recent advances in robotic IPAA surgery.Author (year)Population/designComparison (n)Follow‐upKey findingsAdjusted analysisHanaoka et al. (2024) [12]UC; retrospective cohortRobotic n = 12 vs. laparoscopic n = 21; stapled IPAAFunctional assessment at 12 months after stoma closure Longer operative time (412 vs. 377 min; p = 0.671)Lower blood loss (35 vs. 118 mL; p = 0.032)Comparable 30‐day morbidity (CD ≥ II: 41.7% vs. 42.9%; p = 1.000)Comparable anastomotic leakage (0% vs. 14.3%; p = 0.284) and pouch failure (0% vs. 14.3%; p = 0.284)Comparable hospital stay (8 vs. 10.5 days; p = 0.133)Improved postoperative defecation function (Wexner score: 0 vs. 8 at 12 months; squeeze pressure: 302 vs. 175 mmHg; p = 0.03) No; unadjusted comparisonsViolante et al. (2025) [13]UC or FAP; retrospective cohortRobotic n = 145 vs. laparoscopic n = 107 vs. open n = 149Median after ileostomy closure: 9.1 vs. 14.1 vs. 12.3 months (p = 0.005) Longer operative time (300 vs. 257 vs. 213 min; p < 0.001)Lower conversion rate with robotic surgery vs. laparoscopy (1.4% vs. 17.8%; p < 0.001)Comparable 30‐day morbidity (32.4% vs. 38.3% vs. 25.5%; p = 0.091)Higher VTE/PE rate after robotic/laparoscopic surgery vs. open surgery (5.5%/7.5% vs. 0.7%; p < 0.001)Lower 30‐day readmission rate with robotic surgery vs. laparoscopy (15.9% vs. 28.0%; overall p < 0.001)Comparable pouch failure rate (8.4% vs. 4.7% vs. 6.1%; p = 0.712) Yes; Cox, linear and logistic regression with prespecified covariatesViolante et al. (2025) [14]UC, IC, or FAP; retrospective survey studyRobotic n = 46 vs. laparoscopic n = 112Mean time IPAA‐to‐survey: 58 ± 25 vs. 89 ± 34 months (80 ± 35 overall) Comparable pouch function/QoL (IPSS: 52.0 ± 23.0 vs. 47.0 ± 21.9; p = 0.20)Longer operative time (324 ± 114 vs. 197 ± 59 min; p < 0.0001)Lower blood loss (84 ± 75 vs. 134 ± 105 mL; p = 0.005)Comparable septic complications (4.4% vs. 11.6%; p = 0.22) and ileus (8.7% vs. 17.0%; p = 0.22)Comparable 30‐day readmission rate (6.5% vs. 8.9%; p = 0.82)High patient preference for IPAA over ileostomy (92%) Multilinear regression for factors associated with IPSS; surgical approach comparison largely unadjustedCalabrese et al. (2025) [15]UC; prospective cohortHybrid robotic‐laparoscopic n = 14 vs. laparoscopic n = 1130‐day postoperative outcomes Comparable operative time (300 vs. 325 min; NS)Comparable overall 30‐day morbidity (7.1% vs. 36.4%; NS)Comparable major morbidity (CD ≥ III: 0% vs. 27.3%; NS)Comparable 30‐day readmission (0% vs. 18.2%; NS) and reoperation (0% vs. 9.1%; NS)High trainee participation in laparoscopic colectomy modules (71.4%–92.8%)Feasible hybrid robotic‐laparoscopic approach No; unadjusted comparisonsAbdalla et al. (2026) [16]UC; two‐center retrospective cohortRobotic n = 43 vs. laparoscopic n = 58Functional outcomes at 1 year Longer operative time for robotic RP‐IPAA (342 ± 70 vs. 300 ± 97 min; p = 0.013), but comparable for RPC‐IPAA (429 ± 84 vs. 456 ± 90 min; p = 0.130)Comparable conversion rate (7.0% vs. 13.8%; NS)Comparable postoperative morbidity (39.5% vs. 50.0%; NS)Shorter hospital stay (9.6 ± 4.0 vs. 12.8 ± 6.8 days; p = 0.005)Comparable 1‐year pouch function (IPSS: 47.8 vs. 42.6; NS) No adjusted comparison reported for surgical approachBislenghi et al. (2026) [17]UC; retrospective case seriesSingle‐port robotic IPAA; n = 1430‐day safety; ileostomy closure median 64 days No conversionMean hospital stay: 5.8 daysPostoperative complications: 28.5%Feasible single‐port robotic approach No comparative/adjusted analysis Note: Values and p values are shown when reported in the original studies. Cost was not directly evaluated in these included studies.Abbreviations: CD, clavien‐dindo; FAP, familial adenomatous polyposis; IC, indeterminate colitis; IPAA, ileal pouch–anal anastomosis; IPSS, ileoanal pouch syndrome severity score; NS, not statistically significant; PE, pulmonary embolism; RPC‐IPAA, restorative proctocolectomy with ileal pouch anal anastomosis; RP‐IPAA, restorative proctectomy with IPAA; UC, ulcerative colitis; VTE, venous thromboembolism. Recent advances in robotic IPAA surgery. Longer operative time (412 vs. 377 min; p = 0.671)Lower blood loss (35 vs. 118 mL; p = 0.032)Comparable 30‐day morbidity (CD ≥ II: 41.7% vs. 42.9%; p = 1.000)Comparable anastomotic leakage (0% vs. 14.3%; p = 0.284) and pouch failure (0% vs. 14.3%; p = 0.284)Comparable hospital stay (8 vs. 10.5 days; p = 0.133)Improved postoperative defecation function (Wexner score: 0 vs. 8 at 12 months; squeeze pressure: 302 vs. 175 mmHg; p = 0.03) Longer operative time (412 vs. 377 min; p = 0.671) Longer operative time (412 vs. 377 min; p = 0.671) Lower blood loss (35 vs. 118 mL; p = 0.032) Lower blood loss (35 vs. 118 mL; p = 0.032) Comparable 30‐day morbidity (CD ≥ II: 41.7% vs. 42.9%; p = 1.000) Comparable 30‐day morbidity (CD ≥ II: 41.7% vs. 42.9%; p = 1.000) Comparable anastomotic leakage (0% vs. 14.3%; p = 0.284) and pouch failure (0% vs. 14.3%; p = 0.284) Comparable anastomotic leakage (0% vs. 14.3%; p = 0.284) and pouch failure (0% vs. 14.3%; p = 0.284) Comparable hospital stay (8 vs. 10.5 days; p = 0.133) Comparable hospital stay (8 vs. 10.5 days; p = 0.133) Improved postoperative defecation function (Wexner score: 0 vs. 8 at 12 months; squeeze pressure: 302 vs. 175 mmHg; p = 0.03) Improved postoperative defecation function (Wexner score: 0 vs. 8 at 12 months; squeeze pressure: 302 vs. 175 mmHg; p = 0.03) Longer operative time (300 vs. 257 vs. 213 min; p < 0.001)Lower conversion rate with robotic surgery vs. laparoscopy (1.4% vs. 17.8%; p < 0.001)Comparable 30‐day morbidity (32.4% vs. 38.3% vs. 25.5%; p = 0.091)Higher VTE/PE rate after robotic/laparoscopic surgery vs. open surgery (5.5%/7.5% vs. 0.7%; p < 0.001)Lower 30‐day readmission rate with robotic surgery vs. laparoscopy (15.9% vs. 28.0%; overall p < 0.001)Comparable pouch failure rate (8.4% vs. 4.7% vs. 6.1%; p = 0.712) Longer operative time (300 vs. 257 vs. 213 min; p < 0.001) Longer operative time (300 vs. 257 vs. 213 min; p < 0.001) Lower conversion rate with robotic surgery vs. laparoscopy (1.4% vs. 17.8%; p < 0.001) Lower conversion rate with robotic surgery vs. laparoscopy (1.4% vs. 17.8%; p < 0.001) Comparable 30‐day morbidity (32.4% vs. 38.3% vs. 25.5%; p = 0.091) Comparable 30‐day morbidity (32.4% vs. 38.3% vs. 25.5%; p = 0.091) Higher VTE/PE rate after robotic/laparoscopic surgery vs. open surgery (5.5%/7.5% vs. 0.7%; p < 0.001) Higher VTE/PE rate after robotic/laparoscopic surgery vs. open surgery (5.5%/7.5% vs. 0.7%; p < 0.001) Lower 30‐day readmission rate with robotic surgery vs. laparoscopy (15.9% vs. 28.0%; overall p < 0.001) Lower 30‐day readmission rate with robotic surgery vs. laparoscopy (15.9% vs. 28.0%; overall p < 0.001) Comparable pouch failure rate (8.4% vs. 4.7% vs. 6.1%; p = 0.712) Comparable pouch failure rate (8.4% vs. 4.7% vs. 6.1%; p = 0.712) Comparable pouch function/QoL (IPSS: 52.0 ± 23.0 vs. 47.0 ± 21.9; p = 0.20)Longer operative time (324 ± 114 vs. 197 ± 59 min; p < 0.0001)Lower blood loss (84 ± 75 vs. 134 ± 105 mL; p = 0.005)Comparable septic complications (4.4% vs. 11.6%; p = 0.22) and ileus (8.7% vs. 17.0%; p = 0.22)Comparable 30‐day readmission rate (6.5% vs. 8.9%; p = 0.82)High patient preference for IPAA over ileostomy (92%) Comparable pouch function/QoL (IPSS: 52.0 ± 23.0 vs. 47.0 ± 21.9; p = 0.20) Comparable pouch function/QoL (IPSS: 52.0 ± 23.0 vs. 47.0 ± 21.9; p = 0.20) Longer operative time (324 ± 114 vs. 197 ± 59 min; p < 0.0001) Longer operative time (324 ± 114 vs. 197 ± 59 min; p < 0.0001) Lower blood loss (84 ± 75 vs. 134 ± 105 mL; p = 0.005) Lower blood loss (84 ± 75 vs. 134 ± 105 mL; p = 0.005) Comparable septic complications (4.4% vs. 11.6%; p = 0.22) and ileus (8.7% vs. 17.0%; p = 0.22) Comparable septic complications (4.4% vs. 11.6%; p = 0.22) and ileus (8.7% vs. 17.0%; p = 0.22) Comparable 30‐day readmission rate (6.5% vs. 8.9%; p = 0.82) Comparable 30‐day readmission rate (6.5% vs. 8.9%; p = 0.82) High patient preference for IPAA over ileostomy (92%) High patient preference for IPAA over ileostomy (92%) Comparable operative time (300 vs. 325 min; NS)Comparable overall 30‐day morbidity (7.1% vs. 36.4%; NS)Comparable major morbidity (CD ≥ III: 0% vs. 27.3%; NS)Comparable 30‐day readmission (0% vs. 18.2%; NS) and reoperation (0% vs. 9.1%; NS)High trainee participation in laparoscopic colectomy modules (71.4%–92.8%)Feasible hybrid robotic‐laparoscopic approach Comparable operative time (300 vs. 325 min; NS) Comparable operative time (300 vs. 325 min; NS) Comparable overall 30‐day morbidity (7.1% vs. 36.4%; NS) Comparable overall 30‐day morbidity (7.1% vs. 36.4%; NS) Comparable major morbidity (CD ≥ III: 0% vs. 27.3%; NS) Comparable major morbidity (CD ≥ III: 0% vs. 27.3%; NS) Comparable 30‐day readmission (0% vs. 18.2%; NS) and reoperation (0% vs. 9.1%; NS) Comparable 30‐day readmission (0% vs. 18.2%; NS) and reoperation (0% vs. 9.1%; NS) High trainee participation in laparoscopic colectomy modules (71.4%–92.8%) High trainee participation in laparoscopic colectomy modules (71.4%–92.8%) Feasible hybrid robotic‐laparoscopic approach Feasible hybrid robotic‐laparoscopic approach Longer operative time for robotic RP‐IPAA (342 ± 70 vs. 300 ± 97 min; p = 0.013), but comparable for RPC‐IPAA (429 ± 84 vs. 456 ± 90 min; p = 0.130)Comparable conversion rate (7.0% vs. 13.8%; NS)Comparable postoperative morbidity (39.5% vs. 50.0%; NS)Shorter hospital stay (9.6 ± 4.0 vs. 12.8 ± 6.8 days; p = 0.005)Comparable 1‐year pouch function (IPSS: 47.8 vs. 42.6; NS) Longer operative time for robotic RP‐IPAA (342 ± 70 vs. 300 ± 97 min; p = 0.013), but comparable for RPC‐IPAA (429 ± 84 vs. 456 ± 90 min; p = 0.130) Longer operative time for robotic RP‐IPAA (342 ± 70 vs. 300 ± 97 min; p = 0.013), but comparable for RPC‐IPAA (429 ± 84 vs. 456 ± 90 min; p = 0.130) Comparable conversion rate (7.0% vs. 13.8%; NS) Comparable conversion rate (7.0% vs. 13.8%; NS) Comparable postoperative morbidity (39.5% vs. 50.0%; NS) Comparable postoperative morbidity (39.5% vs. 50.0%; NS) Shorter hospital stay (9.6 ± 4.0 vs. 12.8 ± 6.8 days; p = 0.005) Shorter hospital stay (9.6 ± 4.0 vs. 12.8 ± 6.8 days; p = 0.005) Comparable 1‐year pouch function (IPSS: 47.8 vs. 42.6; NS) Comparable 1‐year pouch function (IPSS: 47.8 vs. 42.6; NS) No conversionMean hospital stay: 5.8 daysPostoperative complications: 28.5%Feasible single‐port robotic approach No conversion No conversion Mean hospital stay: 5.8 days Mean hospital stay: 5.8 days Postoperative complications: 28.5% Postoperative complications: 28.5% Feasible single‐port robotic approach Feasible single‐port robotic approach Note: Values and p values are shown when reported in the original studies. Cost was not directly evaluated in these included studies. Abbreviations: CD, clavien‐dindo; FAP, familial adenomatous polyposis; IC, indeterminate colitis; IPAA, ileal pouch–anal anastomosis; IPSS, ileoanal pouch syndrome severity score; NS, not statistically significant; PE, pulmonary embolism; RPC‐IPAA, restorative proctocolectomy with ileal pouch anal anastomosis; RP‐IPAA, restorative proctectomy with IPAA; UC, ulcerative colitis; VTE, venous thromboembolism. TABLE 2Transanal IPAA surgery.Author (year)Population/designComparison (n)Follow‐upKey findingsAdjusted analysisHanaoka et al. (2024) [18]UC; Retrospective cohortTAMIP‐IPAA 37 vs. traditional handsewn IPAA 7 (71 in short‐term TAMIP analysis)Pouch failure: median 4 vs. 6 years. Function: 6 and 12 months after stoma closure Shorter operative time (289 vs. 443 min; p = 0.006)Lower blood loss (130 vs. 392 mL; p = 0.001)Shorter hospital stay (8 vs. 18 days; p = 0.003)Lower anastomotic leakage rate (8.1% vs. 42.9%; p = 0.041)Lower 30‐day readmission rate (8.1% vs. 57.1%; p = 0.009)Comparable pouch failure rate (8.2% vs. 28.6%; p = 0.173)Improved postoperative defecation function (Wexner score: 8.0 vs. 14.5 at 6 months, p = 0.029; 7.0 vs. 14.0 at 12 months, p = 0.020)Lower hospitalization cost (traditional IPAA: 1.3‐fold higher) No; unadjusted comparisonsDeng et al. (2025) [19]UC; Comparative cohortta‐IPAA 26 vs. transabdominal IPAA 59 (predominantly laparoscopic)Median time from stoma reversal to survey: 13 vs. 48 months Comparable overall pouch function (COREFO adjusted difference: −3.0, 95% CI −11.0 to 4.8; p = 0.45)Comparable urgency, frequency, and incontinence (all NS)Fewer dietary restrictions (OR 0.23, 95% CI 0.08–0.67; p = 0.007)Shorter hospital stay (4 [IQR 3–5] vs. 6 [5–8] days) a Yes; stabilized inverse‐probability weighting for functional outcomesSchmidt et al. (2026) [20]UC; Two‐center retrospective cohortCRD 78 vs. mTME 9830‐day postoperative complications; complete follow‐up Comparable anastomotic leakage rate (4% vs. 4%; adjusted OR 0.6, 95% CI: 0.1–3.0; p = 0.51)Comparable intra‐abdominal abscess rate (3% vs. 2%; adjusted OR 0.7, 95% CI: 0.1–5.4; p = 0.70)Comparable hospital stay (9.5 vs. 7.4 days; adjusted mean difference 1.5 days, 95% CI: −0.1 to 3.1; p = 0.06)Operative time, blood loss, and transfusion data unavailable Yes; sex, age, BMI, ASA class, diverting stoma, and smokingAbbreviations: ASA, american society of anesthesiologists; CI, confidence interval; COREFO, colorectal functional outcome; CRD, close rectal dissection; IPAA, ileal pouch–anal anastomosis; IQR, interquartile range; mTME, modified total mesorectal excision; OR, odds ratio; TAMIP‐IPAA, transanal minimally invasive proctectomy with IPAA; ta‐IPAA, transanal IPAA; UC, ulcerative colitis. a No significance testing was performed for postoperative morbidity or length of stay in Deng et al. because of nonprobability sampling. Cost was not reported in Deng et al. or Schmidt et al. Transanal IPAA surgery. Shorter operative time (289 vs. 443 min; p = 0.006)Lower blood loss (130 vs. 392 mL; p = 0.001)Shorter hospital stay (8 vs. 18 days; p = 0.003)Lower anastomotic leakage rate (8.1% vs. 42.9%; p = 0.041)Lower 30‐day readmission rate (8.1% vs. 57.1%; p = 0.009)Comparable pouch failure rate (8.2% vs. 28.6%; p = 0.173)Improved postoperative defecation function (Wexner score: 8.0 vs. 14.5 at 6 months, p = 0.029; 7.0 vs. 14.0 at 12 months, p = 0.020)Lower hospitalization cost (traditional IPAA: 1.3‐fold higher) Shorter operative time (289 vs. 443 min; p = 0.006) Shorter operative time (289 vs. 443 min; p = 0.006) Lower blood loss (130 vs. 392 mL; p = 0.001) Lower blood loss (130 vs. 392 mL; p = 0.001) Shorter hospital stay (8 vs. 18 days; p = 0.003) Shorter hospital stay (8 vs. 18 days; p = 0.003) Lower anastomotic leakage rate (8.1% vs. 42.9%; p = 0.041) Lower anastomotic leakage rate (8.1% vs. 42.9%; p = 0.041) Lower 30‐day readmission rate (8.1% vs. 57.1%; p = 0.009) Lower 30‐day readmission rate (8.1% vs. 57.1%; p = 0.009) Comparable pouch failure rate (8.2% vs. 28.6%; p = 0.173) Comparable pouch failure rate (8.2% vs. 28.6%; p = 0.173) Improved postoperative defecation function (Wexner score: 8.0 vs. 14.5 at 6 months, p = 0.029; 7.0 vs. 14.0 at 12 months, p = 0.020) Improved postoperative defecation function (Wexner score: 8.0 vs. 14.5 at 6 months, p = 0.029; 7.0 vs. 14.0 at 12 months, p = 0.020) Lower hospitalization cost (traditional IPAA: 1.3‐fold higher) Lower hospitalization cost (traditional IPAA: 1.3‐fold higher) Comparable overall pouch function (COREFO adjusted difference: −3.0, 95% CI −11.0 to 4.8; p = 0.45)Comparable urgency, frequency, and incontinence (all NS)Fewer dietary restrictions (OR 0.23, 95% CI 0.08–0.67; p = 0.007)Shorter hospital stay (4 [IQR 3–5] vs. 6 [5–8] days) a Comparable overall pouch function (COREFO adjusted difference: −3.0, 95% CI −11.0 to 4.8; p = 0.45) Comparable overall pouch function (COREFO adjusted difference: −3.0, 95% CI −11.0 to 4.8; p = 0.45) Comparable urgency, frequency, and incontinence (all NS) Comparable urgency, frequency, and incontinence (all NS) Fewer dietary restrictions (OR 0.23, 95% CI 0.08–0.67; p = 0.007) Fewer dietary restrictions (OR 0.23, 95% CI 0.08–0.67; p = 0.007) Shorter hospital stay (4 [IQR 3–5] vs. 6 [5–8] days) a Shorter hospital stay (4 [IQR 3–5] vs. 6 [5–8] days) a Comparable anastomotic leakage rate (4% vs. 4%; adjusted OR 0.6, 95% CI: 0.1–3.0; p = 0.51)Comparable intra‐abdominal abscess rate (3% vs. 2%; adjusted OR 0.7, 95% CI: 0.1–5.4; p = 0.70)Comparable hospital stay (9.5 vs. 7.4 days; adjusted mean difference 1.5 days, 95% CI: −0.1 to 3.1; p = 0.06)Operative time, blood loss, and transfusion data unavailable Comparable anastomotic leakage rate (4% vs. 4%; adjusted OR 0.6, 95% CI: 0.1–3.0; p = 0.51) Comparable anastomotic leakage rate (4% vs. 4%; adjusted OR 0.6, 95% CI: 0.1–3.0; p = 0.51) Comparable intra‐abdominal abscess rate (3% vs. 2%; adjusted OR 0.7, 95% CI: 0.1–5.4; p = 0.70) Comparable intra‐abdominal abscess rate (3% vs. 2%; adjusted OR 0.7, 95% CI: 0.1–5.4; p = 0.70) Comparable hospital stay (9.5 vs. 7.4 days; adjusted mean difference 1.5 days, 95% CI: −0.1 to 3.1; p = 0.06) Comparable hospital stay (9.5 vs. 7.4 days; adjusted mean difference 1.5 days, 95% CI: −0.1 to 3.1; p = 0.06) Operative time, blood loss, and transfusion data unavailable Operative time, blood loss, and transfusion data unavailable Abbreviations: ASA, american society of anesthesiologists; CI, confidence interval; COREFO, colorectal functional outcome; CRD, close rectal dissection; IPAA, ileal pouch–anal anastomosis; IQR, interquartile range; mTME, modified total mesorectal excision; OR, odds ratio; TAMIP‐IPAA, transanal minimally invasive proctectomy with IPAA; ta‐IPAA, transanal IPAA; UC, ulcerative colitis. No significance testing was performed for postoperative morbidity or length of stay in Deng et al. because of nonprobability sampling. Cost was not reported in Deng et al. or Schmidt et al. Rise of Robotic Surgery in UC Recent advances in robotic IPAA surgery are shown in Table 1. Robotic surgery is one of the most important technological advancements in the surgical management of UC. Although laparoscopic surgery remains the standard minimally invasive approach for restorative proctocolectomy with IPAA, complex pelvic dissection and pouch construction continue to represent considerable technical challenges, particularly in men or patients with obesity or a narrow pelvis [21]. Robotic platforms were introduced to overcome these limitations by providing enhanced dexterity, three‐dimensional visualization, tremor filtration, and articulated instruments [22]. The adoption of robotic surgery for UC has increased rapidly in recent years [12, 13, 14, 15, 16, 17]. National database analyses showed that the proportion of robotic procedures increased from 7.4% of UC operations in 2016 to 24.1% in 2022, reflecting growing surgeons' experience and wider availability of robotic platforms in the United States [23]. This trend parallels the broader expansion of robotic colorectal surgery worldwide. Recent evidence suggests that robotic‐assisted IPAA provides several perioperative advantages. Recent meta‐analyses have shown that robotic‐assisted IPAA offers distinct perioperative advantages. A primary benefit is a shorter hospital stay, with robotic patients staying an average of 1.1 days less than those undergoing non‐robotic (laparoscopic or open) surgery for UC or familial adenomatous polyposis [21]. These findings suggest that improved visualization and maneuverability of instruments facilitate safer pelvic dissection in technically demanding cases. Despite these advantages, robotic surgery remains associated with longer operative times and high procedural costs [21]. Furthermore, the quality of currently available evidence is limited by the predominance of retrospective studies and institutional experiences [21]. As robotic technology continues to evolve, newer platforms are being developed to further minimize surgical invasiveness. One such innovation is single‐port (SP) robotic surgery, which enables complex procedures to be performed through a single access site. Using a single incision, including pre‐existing ileostomy sites, SP platforms may further reduce abdominal wall trauma, decrease the number of trocar‐related wounds, and improve cosmetic outcomes [24]. Early clinical experiences have demonstrated the feasibility and safety of SP robotic restorative proctocolectomy in carefully selected patients, suggesting a potential future direction for minimally invasive UC surgery [17]. Nevertheless, the continued expansion of robotic platforms, together with accumulating clinical evidence, suggest that robotic surgery is increasingly becoming an important component of contemporary UC surgery [21]. Ongoing efforts to optimize training pathways and improve operative efficiency of robotic surgery will likely further define its role in the future [25]. Transanal Minimally Invasive Proctectomy Parallel to robotic advancements, transanal approaches, such as transanal minimally invasive proctectomy (TAMIP)‐IPAA and transanal IPAA, have overcome the technical limitations of deep pelvic dissection. By combining abdominal laparoscopy with transanal rectal dissection, these techniques provide improved visualization of the distal rectum and facilitate precise rectal cuff preservation, particularly in challenging pelvic anatomy. Recent evidence has also shown favorable functional outcomes of transanal IPAA [18, 19, 20] (Table 2). In an inverse‐probability weighting analysis of 85 patients with UC, transanal IPAA achieved bowel, urinary, sexual, and quality of life outcomes comparable to those of conventional laparoscopic IPAA, without compromising long‐term pouch function [19]. These findings suggest transanal IPAA as a safe and function‐preserving alternative that may further reduce the invasiveness of restorative proctocolectomy. However, the current evidence is largely derived from retrospective studies with relatively small sample sizes. High‐quality prospective studies and randomized controlled trials are needed to confirm its long‐term benefits and clarify appropriate patient selection. Pouch Disorders and Outcomes After IPAA for UC The clinical management of pouchitis and Crohn's‐like disease of the pouch has shifted toward immune‐targeted advanced therapies. The 2024 AGA clinical practice guideline [26] established standardized definitions for intermittent, chronic antibiotic‐dependent and chronic antibiotic‐refractory pouchitis, recommending biologics and oral small molecules for refractory cases. Data from a population‐based cohort study from the United States showed that pouchitis was the most common postoperative complication, affecting 48% of patients within 2 years and up to 80% over their lifetime [26]. Approximately 17% of patients develop chronic symptoms, and 10% progress to Crohn's‐like disease of the pouch [26]. The landmark EARNEST trial provided the first robust evidence for vedolizumab in chronic pouchitis and reported a clinical remission rate of 31% at Week 14 compared with 10% for the placebo group [27]. Recent post hoc analyses of the EARNEST trial further showed that vedolizumab induced mucosal healing in 16.7% of patients (vs. 2.5% for placebo), which was strongly associated with improved quality of life and sustained remission [27]. A 2025 multicenter study showed that ustekinumab was more effective than vedolizumab for Crohn's‐like disease of the pouch, with a higher clinical response at 3 and 6 months, as well as longer treatment durability [28]. A meta‐analysis of 99 subjects with chronic pouchitis showed pooled clinical and endoscopic response rates of 47.7% and 51.7%, respectively, and the remission rate was 41.2% [29]. Despite high adverse event (30.9%) and discontinuation (43%) rates, tofacitinib is a promising alternative for refractory cases under close monitoring [29, 30]. These insights highlight an evolving paradigm where advanced immunological treatments are prioritized when traditional antibiotics fail. CD Overall Trends in Surgical Rates The role of surgery in CD has evolved considerably over the past several decades. The widespread use of immunomodulators and biologic therapies is associated with a substantial reduction in primary intestinal resection rates [31, 32, 33]. Consistent with this trend, a recent analysis of more than 42 000 patients from Norway and Sweden reported that the 5‐year cumulative probability of surgery decreased from 30.1% in 1987–1994 to 13.9% in 2011–2017 [34]. Similar trends have been reported in Asia and South America, with recent studies from China and Brazil showing declining surgical rates in parallel with advances in disease monitoring and medical therapy [35, 36]. Despite this decline, surgery remains an essential component of managing CD. While modern medical therapies have improved control of inflammatory disease and reduced overall surgical rates, their ability to prevent or reverse established fibrosis remains limited. Recent nationwide data from the United States showed that hospitalizations for CD‐related bowel resection decreased from 12.0% of all CD hospitalizations in 1998 to 6.9% in 2020. In contrast, the proportion of resections performed for bowel obstruction increased from 10.8% to 29.1% during the same period [37]. These findings suggest that current anti‐inflammatory therapies have limited efficacy against fibrostenotic disease. Therefore, surgery remains the definitive treatment for patients with established intestinal strictures. A recent four‐decade population‐based study showed persistently high rates of perianal surgery despite increasing use of biologic therapies, highlighting the ongoing need for surgical intervention in this patient population [38]. Collectively, these findings suggest that although surgery is required less frequently overall, it remains indispensable for patients with fibrostenotic, penetrating, and perianal disease. Kono‐S Anastomosis Kono‐S anastomosis remains a pivotal surgical strategy for reducing postoperative recurrence of CD. Landmark data from the SuPREMe‐CD study, a randomized, controlled trial, established the clinical efficacy of Kono‐S anastomosis. This study showed that 6‐month endoscopic recurrence was lower with Kono‐S anastomosis than with conventional side‐to‐side anastomosis [39]. Recent evidence published in 2024 further corroborated these findings. In a meta‐analysis of 17 studies involving 2087 patients undergoing ileocolic resection for CD, the primary endpoint was endoscopic postoperative recurrence occurring ≥ 6 months after surgery. Kono‐S anastomosis reduced the pooled incidence of endoscopic postoperative recurrence to 24.7% compared with 42.6% for conventional anastomotic techniques [40]. A contemporary trend is the transition to stapled Kono‐S techniques. Studies have shown that these versions are safe, reproducible, and faster, reducing the operative time by a median of 52 min [41]. Finally, ongoing high‐quality trials (e.g., MEErKAT) are investigating potential synergistic benefits of combining Kono‐S with extended mesenteric excision [42]. Extended Mesenteric Resection The mesentery is a potential therapeutic target in CD. Traditionally, intestinal resection for CD has followed a mesenteric‐sparing strategy, and current European Crohn's and Colitis Organization guidelines [6] continue to support limited mesenteric excision. However, increasing evidence suggests that the mesentery plays an active part in the pathophysiology of CD. Characteristic findings, such as creeping fat, mesenteric thickening, lymphatic dysfunction, and mesenteric immune activation, have led to renewed interest in more extensive mesenteric resection. Extended mesenteric resection (EMR) involves removal of the diseased mesentery up to its vascular origin during intestinal resection [43, 44]. Early observational studies generated considerable enthusiasm for this approach. Coffey et al. reported a reduction in surgical recurrence from 40% to 2.9% following mesenteric inclusion during ileocolic resection [43], while Zhu et al. showed improved surgical recurrence‐free survival in patients undergoing EMR for Crohn's colitis [45]. These findings support the hypothesis that the mesentery contributes directly to postoperative disease recurrence. However, recent evidence has produced conflicting results. Several recent meta‐analyses reported lower reoperation rates following EMR [46, 47, 48], whereas others failed to show significant advantages compared with limited mesenteric excision [44, 49, 50]. Furthermore, most studies that evaluated EMR have not consistently demonstrated a reduction in short‐term endoscopic recurrence [44, 46, 47, 48, 49, 50]. Importantly, EMR appears to be safe, with postoperative morbidity, anastomotic leak rates, and a length of hospital stay generally comparable to conventional approaches [44, 46, 47, 48, 49, 50]. This ongoing controversy is highlighted by two recent randomized, controlled trials (Table 3). The SPICY trial found no significant difference in postoperative endoscopic recurrence between mesenteric‐sparing surgery and EMR [51]. In contrast, a prespecified interim analysis of the MESOCOLIC trial reported lower endoscopic recurrence following radical mesenteric excision than with conventional mesenteric‐sparing resection [52]. However, these findings should be interpreted with caution because endoscopic recurrence was a secondary endpoint, whereas the original primary endpoint of the trial was surgical recurrence [53]. In addition, concerns have been raised regarding statistical power for endoscopic recurrence, the method of endoscopic assessment, and the distribution of Rutgeerts scores [54]. Differences in the operative technique, extent of mesenteric removal, patient selection, and follow‐up duration may explain these discrepancies between studies. In particular, the MESOCOLIC trial used a more radical oncologic‐style mesenteric excision including the ileocolic vascular trunk, whereas the SPICY trial used a more limited mesenteric resection strategy [51, 52]. TABLE 3Comparison of the SPICY and MESOCOLIC randomized, controlled trials evaluating mesenteric resection in Crohn's disease.CharacteristicSPICY Trial (2024) [51]MESOCOLIC Trial (2025) [52]Study designInternational multicenter RCTMulticenter RCTCountryThe Netherlands and ItalyChinaPatients randomized139116Analysis population131 patients111 (ITT) and 85 (per‐protocol) patientsDisease locationL1 or L3 Crohn's disease requiring primary ileocolic resectionCD was limited to the terminal ileum and/or right colon requiring primary ileocolic resectionMesenteric‐sparing surgeryThe mesentery was divided close to the bowel according to ECCO recommendationsLME with the mesentery divided within 3 cm of the bowelExtended mesenteric resectionMesenteric resection up to the ileocolic trunk while preserving the ileocolic vesselsEME including resection of the ileocolic trunk and diseased mesentery in an oncologic‐style fashionPrimary endpointEndoscopic recurrence at 6 months (Rutgeerts ≥ i2b)Surgical recurrence during 5‐year follow‐upPublished endoscopic analysisFinal analysis of the primary endpointPrespecified interim analysis at 6–18 months (Rutgeerts > i2); endoscopic recurrence was a secondary endpointEndoscopic recurrence42% vs. 43% (EMR vs. control)23.8% vs. 46.5% (EME vs. LME), p = 0.03Modified endoscopic recurrence (≥ i2b)No significant difference19.0% vs. 34.9%, p = 0.10Severe recurrence (i3–i4)No significant difference2.4% vs. 14.0%, p = 0.05Anastomotic leakage8% vs. 2% (non‐significant increase in EMR group)1.7% vs. 0% (similar between groups)Main conclusionExtended mesenteric resection did not reduce postoperative endoscopic recurrence and does not support changing current ECCO recommendationsThe prespecified interim analysis reported lower endoscopic recurrence after EME than LME; however, the long‐term clinical benefit remains uncertain pending analysis of the primary endpointKey limitationFollow‐up limited to 6 monthsInterim analysis not powered for endoscopic recurrence; the primary endpoint of surgical recurrence requires longer follow‐up Note: The 2025 MESOCOLIC publication reports a prespecified interim analysis of endoscopic recurrence and does not represent the final analysis of the trial's primary endpoint (surgical recurrence).Abbreviations: ECCO, european crohn's and colitis organization; EME, extensive mesenteric excision; EMR, extended mesenteric resection; ITT, intention‐to‐treat.LME, limited mesenteric excision; RCT, randomized, controlled trial. Comparison of the SPICY and MESOCOLIC randomized, controlled trials evaluating mesenteric resection in Crohn's disease. Note: The 2025 MESOCOLIC publication reports a prespecified interim analysis of endoscopic recurrence and does not represent the final analysis of the trial's primary endpoint (surgical recurrence). Abbreviations: ECCO, european crohn's and colitis organization; EME, extensive mesenteric excision; EMR, extended mesenteric resection; ITT, intention‐to‐treat.LME, limited mesenteric excision; RCT, randomized, controlled trial. At present, the clinical benefit of EMR remains unclear. Nevertheless, this concept has fundamentally changed the understanding of mesenteric involvement in CD and represents one of the most actively investigated areas in contemporary IBD surgery. Ongoing trials, including MEErKAT [42] and EXCEED [55], are expected to further clarify the role of mesenteric resection in preventing postoperative recurrence. Minimally Invasive Surgery for CD Although evidence remains limited, an increasing number of studies have reported favorable outcomes of robotic‐assisted surgery for CD. Representative reports published between 2024 and June 2026 are summarized in Table 4 [56, 57, 58, 59]. These studies highlight the growing application of robotic platforms in complex CD surgery and provide early evidence supporting their technical feasibility and clinical safety. Building upon these observations, recent systematic reviews and meta‐analyses have shown that robotic ileocolic resection achieves perioperative outcomes comparable to those of laparoscopic surgery, while potentially reducing conversion rates and the length of hospital stay [11, 60, 61]. These potential advantages may be particularly relevant in technically challenging cases, where enhanced dexterity and improved visualization facilitate dissection in the setting of severe inflammation, fistulizing disease, or obesity. TABLE 4Recent advances in robotic surgery for Crohn's disease.Author (year)Population/designComparison (n)/follow‐upProcedureKey findingsAdjusted analysisViolante et al. (2024) [54]Penetrating CD; Retrospective cohortRobotic ICR 33 vs. open ICR 104 30‐day outcomesRobotic vs. open ICR Longer operative time (228 vs. 166 min; p < 0.001)Lower blood loss (61 vs. 270 mL; p < 0.001)Shorter hospital stay (4.5 vs. 6.9 days; p = 0.01)Lower SSI rate (0% vs. 15.4%; p = 0.01)Lower 30‐day readmission rate (0% vs. 15.4%; p = 0.01) No adjusted analysis of postoperative outcomes; regression only for operative timeSmalbroek et al. (2024) [55]Refractory ileal CD with stenosis; Prospective case seriesRobotic Kono‐S, n = 20; no comparator 30‐day complications; endoscopy at 6 monthRobotic intracorporeal Kono‐S Technical success rate: 100%; no conversionMedian operative time: 155 min (IQR 144–176)Median blood loss: 30 mL (IQR 10–50)Median hospital stay: 3 days (IQR 1–5)Anastomotic leakage: 5%; postoperative complications: 3/20 a ; major morbidity (CD ≥ III): 10%30‐day readmission and reoperation rates: 5% each; no 30‐day mortality No; descriptive analysis onlyWong et al. (2025) [56]Pediatric CD; Retrospective case seriesRobotic ICR, n = 6; no comparator. Short‐term outcomesRobotic ileocecal resection with intracorporeal anastomosis No intraoperative complications or conversionsMean operative time: 211 minReturn of bowel function on POD 3Mean hospital stay: 8 daysMajor complication requiring reoperation: 16.7% No; descriptive analysis onlyLiu et al. (2026) [57]Primary ileocolic CD; Retrospective multicenter cohort Robotic ICR 82 vs. laparoscopic ICR 232 Endoscopic FU 11.5 month; clinical FU 37.6 month (medians) Robotic vs. laparoscopic primary ICR Lower conversion rate (3.7% vs. 11.2%; p = 0.05)Longer operative time with robotic surgery (~60 min)Shorter hospital stay (3.2 vs. 3.7 days)Comparable overall/major complications and 30‐day readmissionComparable endoscopic recurrence‐free survival (71.8% vs. 73.0% at 1 year; 51.4% vs. 55.9% at 3 years; p = 0.82)Comparable clinical recurrence (20.7% vs. 27.2%; p = 0.30) and surgical recurrence (3.7% vs. 0.9%; p = 0.11)No association between surgical approach and endoscopic recurrence after adjustment (HR 1.03, 95% CI 0.63–1.69; p = 0.89) Yes; multivariable Cox regression adjusted for propensity scoreAbbreviations: CD, crohn's disease; CD (grade), clavien–dindo; CI, confidence interval; CR, clinical recurrence; ER, endoscopic recurrence; FU, follow‐up; HR, hazard ratio; ICR, ileocolic resection; IQR, interquartile range; POD, postoperative day; SR, surgical recurrence; SSI, surgical site infection. a Smalbroek et al. reported 3 postoperative complications as 20% in the original table; 3/20 corresponds to 15%. The value is reproduced as reported in the source where applicable. Recent advances in robotic surgery for Crohn's disease. Longer operative time (228 vs. 166 min; p < 0.001)Lower blood loss (61 vs. 270 mL; p < 0.001)Shorter hospital stay (4.5 vs. 6.9 days; p = 0.01)Lower SSI rate (0% vs. 15.4%; p = 0.01)Lower 30‐day readmission rate (0% vs. 15.4%; p = 0.01) Longer operative time (228 vs. 166 min; p < 0.001) Longer operative time (228 vs. 166 min; p < 0.001) Lower blood loss (61 vs. 270 mL; p < 0.001) Lower blood loss (61 vs. 270 mL; p < 0.001) Shorter hospital stay (4.5 vs. 6.9 days; p = 0.01) Shorter hospital stay (4.5 vs. 6.9 days; p = 0.01) Lower SSI rate (0% vs. 15.4%; p = 0.01) Lower SSI rate (0% vs. 15.4%; p = 0.01) Lower 30‐day readmission rate (0% vs. 15.4%; p = 0.01) Lower 30‐day readmission rate (0% vs. 15.4%; p = 0.01) Technical success rate: 100%; no conversionMedian operative time: 155 min (IQR 144–176)Median blood loss: 30 mL (IQR 10–50)Median hospital stay: 3 days (IQR 1–5)Anastomotic leakage: 5%; postoperative complications: 3/20 a ; major morbidity (CD ≥ III): 10%30‐day readmission and reoperation rates: 5% each; no 30‐day mortality Technical success rate: 100%; no conversion Technical success rate: 100%; no conversion Median operative time: 155 min (IQR 144–176) Median operative time: 155 min (IQR 144–176) Median blood loss: 30 mL (IQR 10–50) Median blood loss: 30 mL (IQR 10–50) Median hospital stay: 3 days (IQR 1–5) Median hospital stay: 3 days (IQR 1–5) Anastomotic leakage: 5%; postoperative complications: 3/20 a ; major morbidity (CD ≥ III): 10% Anastomotic leakage: 5%; postoperative complications: 3/20 a ; major morbidity (CD ≥ III): 10% 30‐day readmission and reoperation rates: 5% each; no 30‐day mortality 30‐day readmission and reoperation rates: 5% each; no 30‐day mortality No intraoperative complications or conversionsMean operative time: 211 minReturn of bowel function on POD 3Mean hospital stay: 8 daysMajor complication requiring reoperation: 16.7% No intraoperative complications or conversions No intraoperative complications or conversions Mean operative time: 211 min Mean operative time: 211 min Return of bowel function on POD 3 Return of bowel function on POD 3 Mean hospital stay: 8 days Mean hospital stay: 8 days Major complication requiring reoperation: 16.7% Major complication requiring reoperation: 16.7% Robotic ICR 82 vs. laparoscopic ICR 232 Endoscopic FU 11.5 month; clinical FU 37.6 month (medians) Lower conversion rate (3.7% vs. 11.2%; p = 0.05)Longer operative time with robotic surgery (~60 min)Shorter hospital stay (3.2 vs. 3.7 days)Comparable overall/major complications and 30‐day readmissionComparable endoscopic recurrence‐free survival (71.8% vs. 73.0% at 1 year; 51.4% vs. 55.9% at 3 years; p = 0.82)Comparable clinical recurrence (20.7% vs. 27.2%; p = 0.30) and surgical recurrence (3.7% vs. 0.9%; p = 0.11)No association between surgical approach and endoscopic recurrence after adjustment (HR 1.03, 95% CI 0.63–1.69; p = 0.89) Lower conversion rate (3.7% vs. 11.2%; p = 0.05) Lower conversion rate (3.7% vs. 11.2%; p = 0.05) Longer operative time with robotic surgery (~60 min) Longer operative time with robotic surgery (~60 min) Shorter hospital stay (3.2 vs. 3.7 days) Shorter hospital stay (3.2 vs. 3.7 days) Comparable overall/major complications and 30‐day readmission Comparable overall/major complications and 30‐day readmission Comparable endoscopic recurrence‐free survival (71.8% vs. 73.0% at 1 year; 51.4% vs. 55.9% at 3 years; p = 0.82) Comparable endoscopic recurrence‐free survival (71.8% vs. 73.0% at 1 year; 51.4% vs. 55.9% at 3 years; p = 0.82) Comparable clinical recurrence (20.7% vs. 27.2%; p = 0.30) and surgical recurrence (3.7% vs. 0.9%; p = 0.11) Comparable clinical recurrence (20.7% vs. 27.2%; p = 0.30) and surgical recurrence (3.7% vs. 0.9%; p = 0.11) No association between surgical approach and endoscopic recurrence after adjustment (HR 1.03, 95% CI 0.63–1.69; p = 0.89) No association between surgical approach and endoscopic recurrence after adjustment (HR 1.03, 95% CI 0.63–1.69; p = 0.89) Abbreviations: CD, crohn's disease; CD (grade), clavien–dindo; CI, confidence interval; CR, clinical recurrence; ER, endoscopic recurrence; FU, follow‐up; HR, hazard ratio; ICR, ileocolic resection; IQR, interquartile range; POD, postoperative day; SR, surgical recurrence; SSI, surgical site infection. Smalbroek et al. reported 3 postoperative complications as 20% in the original table; 3/20 corresponds to 15%. The value is reproduced as reported in the source where applicable. Despite these benefits, robotic surgery remains associated with longer operative times, with recent meta‐analyses reporting an average increase of approximately 60–70 min compared with laparoscopy [11, 61]. Furthermore, the current evidence is derived predominantly from retrospective studies and is subject to selection bias and institutional heterogeneity. Overall, robotic‐assisted surgery appears to be a safe and effective minimally invasive option for selected patients with CD and may provide advantages in perioperative recovery and conversion avoidance. However, prospective, multicenter studies are required to better define the long‐term benefits, cost‐effectiveness, and optimal indications of robotic‐assisted surgery. Postoperative Recurrence Postoperative recurrence remains one of the major challenges in managing CD. In the absence of prophylactic therapy, endoscopic recurrence occurs in approximately 70%–90% of patients within the first year after surgery [62]. Current international guidelines advocate a risk‐stratified approach, recommending early prophylactic treatment for patients with established risk factors, such as active smoking, penetrating disease, and prior intestinal resection [6, 63]. In parallel, postoperative management has shifted toward a treat‐to‐target strategy. The landmark POCER trial showed that ileocolonoscopy at 6 months followed by treatment escalation according to endoscopic findings considerably improved outcomes, forming the basis of current European Crohn's and Colitis Organization and AGA recommendations for routine postoperative endoscopic monitoring [64]. Anti‐TNF agents remain the most effective established therapies for preventing postoperative recurrence [65, 66, 67, 68]. A recent network meta‐analysis including 42 studies and 3861 patients showed that infliximab and adalimumab provided the greatest protection against postoperative recurrence, followed by vedolizumab, whereas thiopurines and antibiotics showed lower efficacy [68]. Recent evidence has expanded the range of available biologic options. The REPREVIO trial provided the first randomized evidence supporting vedolizumab for preventing endoscopic postoperative recurrence in high‐risk patients [69]. In addition, ustekinumab has emerged as a promising alternative, particularly in patients with previous anti‐TNF exposure or treatment failure [70, 71]. Recent reports have suggested that biologic prophylaxis should be initiated within 4 weeks after surgery because histological disease activity may begin within days of restoring fecal continuity [72]. However, long‐term management requires a “treat‐to‐target” strategy, incorporating a mandatory ileocolonoscopy at 6 months and regular monitoring of noninvasive biomarkers, such as fecal calprotectin, to guide therapeutic adjustments [6]. Perianal CD Perianal Crohn's disease (pCD), particularly complex fistulizing disease, remains one of the most challenging manifestations of CD and is associated with substantial morbidity and impaired quality of life [6]. Contemporary management of pCD is based on a multidisciplinary approach combining medical and surgical therapies [6]. A systematic review and meta‐analysis of pCD by Yassin et al. showed that combined treatment with surgical intervention, such as seton drainage and medical therapy, achieved superior fistula healing compared with either strategy alone [73]. Anti‐TNF agents remain the cornerstone of medical treatment for pCD and currently provide the strongest evidence for induction and maintenance of fistula remission. Consequently, infliximab and adalimumab are recommended as first‐line biologic therapies in current guidelines [6]. In patients with anti‐TNF failure or intolerance, vedolizumab and ustekinumab have emerged as effective alternative options, although the level of evidence remains lower than that for anti‐TNF therapy [6]. Recently, novel therapeutic approaches for pCD have attracted increasing interest. Studies have suggested that the selective Janus kinase 1 inhibitor upadacitinib may promote fistula closure in refractory pCD, although dedicated prospective studies are still required to establish its role [74]. Recent studies have further refined the surgical management of pCD. Seton drainage remains an important component of treatment, although the optimal timing of removal remains uncertain. A 2026 meta‐analysis of nine studies reported a healing rate of 57% and a recurrence rate of 31% after seton removal. Short‐term removal (< 34 weeks) was associated with a higher healing rate than long‐term removal (69% vs. 46%), without a significant increase in recurrence; however, these findings may be influenced by disease severity and treatment response [75]. In selected patients, sphincter‐preserving procedures such as advancement flap (AF) and ligation of the intersphincteric fistula tract (LIFT) may be considered. A 2026 review reported AF healing rates of 23%–91%, although evidence remains limited [76]. A 2025 network meta‐analysis of 3520 patients undergoing sphincter‐preserving procedures showed a higher failure rate in patients with CD (39.5% vs. 31.4%), highlighting the challenges of definitive fistula closure in this population [77]. Darvadstrocel, an allogeneic adipose‐derived mesenchymal stem cell therapy, has shown mixed results in refractory pCD. In the ADMIRE‐CD trial, darvadstrocel achieved a higher rate of combined remission of pCD than placebo at 52 weeks [78]. However, the subsequent ADMIRE‐CD II trial failed to meet its primary endpoint [79]. Although no new safety concerns were identified, the failure to confirm efficacy led to withdrawal of its marketing authorization in the European Union in December 2024. In Japan, discontinuation of Alofisel has also been announced. Proctectomy remains a salvage option for severe refractory pCD, but perineal wound healing remains a major concern [80]. A 2025 multicenter study also demonstrated slower perineal wound healing after proctectomy in CD than in UC (adjusted HR 0.67), with 12‐month healing rates of 79% and 91%, respectively [81]. Overall, current evidence supports a multidisciplinary treatment strategy combining anti‐TNF therapy and appropriate surgical management as the foundation of pCD treatment. New biologics and small‐molecule therapies continue to expand therapeutic options for refractory pCD, although their precise roles remain to be fully established. Future Perspectives and Conclusions Recent advances in medical and surgical therapies have substantially improved the management of IBD. Nevertheless, several important challenges remain. In CD, considerable interest continues to focus on strategies aimed at reducing postoperative recurrence and reoperation. Further studies are required to clarify the long‐term benefits of novel anastomotic techniques and mesentery‐based surgical approaches. Technological innovation is also expected to shape the future of IBD surgery. Continued development of robotic platforms, including single‐port systems, may further enhance surgical precision while reducing invasiveness. In conclusion, surgery remains an essential component of contemporary IBD care despite remarkable advances in medical therapy. Future progress will depend on close collaboration between gastroenterologists and surgeons, with the shared goal of optimizing long‐term disease control, preserving bowel function, and improving quality of life for patients with IBD. Author Contributions Yuhki Koike: writing – review and editing. Yoshiki Okita: conceptualization, methodology, writing – original draft, writing – review and editing. Yuji Toiyama: conceptualization, writing – review and editing. Tadanobu Shimura: writing – review and editing. Mikio Kawamura: writing – review and editing. Funding The authors have nothing to report. Ethics Statement The authors have nothing to report. Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments We thank Ellen Knapp, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the current study. References Associated Data Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the current study.